Impax announces FDA approval and launch of generic version of Vytorin®
Impax Laboratories announced it has received final FDA approval for a generic version of Vytorin® (ezetimibe/simvastatin tablets), 10/10, 10/20, 10/40 and 10/80 mg, and immediately initiated commercialization activities of this first-to-market opportunity. April 26, 2017